Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$13.78 +1.49%

+$0.37 today

Market cap
$1.22B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.39M

Average 1.48M

MLYS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Mineralys Therapeutics, Inc.NASDAQ: MLYS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$241.07M, compared with -$43.26M a year earlier. Trailing-twelve-month EBITDA was -$349.54M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +13.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$241.07M-512.9% QoQ
Last fiscal yearDec 2025
-$154.59M+13.0% YoY
LTMJun 2026
-$349.54M-83.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-457.3%+100.0%+557.3 pp
1 year+13.0%+100.0%+87.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(154.59M) USD
Year-over-year change
+13.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MLYS compares with its peers on the latest reported figures

  • MLYS's LTM Jun 2026 EBITDA of -$349.54M is the 6th highest of the 7 companies compared; the peer median is -$79.65M.
  • Its year-over-year change of -83.3% is the 3rd highest of 7, against a peer median of -125.5%.
MLYS Competitors Peer median
EBITDA for MLYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$35.03M -30.1%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.25M -164.0%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M +20.1%—161.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$106.58M -372.0%—16.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$119.51M -312.9%—597.6%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$349.54M -83.3%——
VERAVera Therapeutics, Inc.LTM Jun 2026-$393.82M -87.1%——
Peer median (excluding MLYS) -$79.65M-125.5%—161.1%

Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development16.31M26.25M70.36M168.58M132.01M
Selling, General & Admin2.42M5.23M14.3M23.82M38.6M
Operating Expenses18.73M31.48M84.66M192.4M170.6M
Depreciation & Amortization00043K59K
EBITDA(19.38M)(28.12M)(71.9M)(177.77M)(154.59M)
EBITDA Margin—————
Operating Income(18.73M)(31.48M)(84.66M)(192.4M)(170.6M)
Operating Margin—————
Interest Income01.68M12.76M14.59M15.95M
Interest Expense27K1.68M000
Other Income / Expenses(683K)1.68M12.76M14.59M15.95M
Income Before Tax(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Net Margin—————
EPS (Basic)(3.89)(5.77)(1.99)(3.66)(2.29)
EPS (Diluted)(3.89)(5.77)(1.99)(3.66)(2.29)
Weighted Avg Shares4.98M5.17M36.19M48.54M67.66M
Weighted Avg Shares (Diluted)4.98M5.17M36.19M48.54M67.66M

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Intrinsic Alpha fair value

Locked

Current Price

$13.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.